Home Biosimilar Antibodies Apoptosis Others lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)
For research use only. Not for use in humans.

lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Synonyms: HGS-ETR 2, ETR2-ST01

Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW : 145.5 KD.

lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Quality Control

Batch: A233001 Purity: 99% Protein concentration: 4.69mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW : 145.5 KD.

Product Details

CAS No. 845816-02-6
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.